Companies › Elicio Therapeutics
1 active drug program in 2 registered trials: 2 Phase 1; Oncology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ELI-002 7P Lipid-conjugated CpG oligonucleotide (Amph-CpG-7909) plus lipid-conjugated peptide-based a | KRAS, NRAS | Phase 1 | Pancreatic Ductal Adenocarcinoma; Pancreatic Cancer | Nov 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05726864 | ELI-002 7P | Phase 1 | Pancreatic Ductal Adenocarcinoma | Oncology | Nov 2026 |
| NCT07671339 | ELI-002 7P | Phase 1 | Pancreatic Cancer | Oncology | Jun 2028 |
Cash of $31m on 2026-09-30; operating cash outflow about $40m a year; runway about 9 months at that burn, to Jul 2027
Press releases filed as 8-K in the last year:
Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.